JP2005521650A5 - - Google Patents

Download PDF

Info

Publication number
JP2005521650A5
JP2005521650A5 JP2003559997A JP2003559997A JP2005521650A5 JP 2005521650 A5 JP2005521650 A5 JP 2005521650A5 JP 2003559997 A JP2003559997 A JP 2003559997A JP 2003559997 A JP2003559997 A JP 2003559997A JP 2005521650 A5 JP2005521650 A5 JP 2005521650A5
Authority
JP
Japan
Prior art keywords
pyrazinyl
methoxy
benzenesulfonamide
dichloro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003559997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521650A (ja
JP4504021B2 (ja
Filing date
Publication date
Priority claimed from SE0200119A external-priority patent/SE0200119D0/xx
Priority claimed from SE0201857A external-priority patent/SE0201857D0/xx
Application filed filed Critical
Priority claimed from PCT/SE2003/000041 external-priority patent/WO2003059893A1/en
Publication of JP2005521650A publication Critical patent/JP2005521650A/ja
Publication of JP2005521650A5 publication Critical patent/JP2005521650A5/ja
Application granted granted Critical
Publication of JP4504021B2 publication Critical patent/JP4504021B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003559997A 2002-01-16 2003-01-14 N−ピラジニル−フェニルスルホンアミド、およびケモカイン介在疾患の処置におけるそれらの使用 Expired - Fee Related JP4504021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200119A SE0200119D0 (sv) 2002-01-16 2002-01-16 Novel compounds
SE0201857A SE0201857D0 (sv) 2002-06-17 2002-06-17 Novel compounds
PCT/SE2003/000041 WO2003059893A1 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

Publications (3)

Publication Number Publication Date
JP2005521650A JP2005521650A (ja) 2005-07-21
JP2005521650A5 true JP2005521650A5 (https=) 2006-03-02
JP4504021B2 JP4504021B2 (ja) 2010-07-14

Family

ID=26655657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559997A Expired - Fee Related JP4504021B2 (ja) 2002-01-16 2003-01-14 N−ピラジニル−フェニルスルホンアミド、およびケモカイン介在疾患の処置におけるそれらの使用

Country Status (21)

Country Link
US (2) US7662825B2 (https=)
EP (1) EP1467976B1 (https=)
JP (1) JP4504021B2 (https=)
KR (1) KR20040073566A (https=)
CN (1) CN100357275C (https=)
AR (1) AR038179A1 (https=)
AT (1) ATE534635T1 (https=)
AU (1) AU2003201802A1 (https=)
BR (1) BR0306922A (https=)
CA (1) CA2472204A1 (https=)
CO (1) CO5640137A2 (https=)
ES (1) ES2375107T3 (https=)
IL (1) IL162678A0 (https=)
IS (1) IS7348A (https=)
MX (1) MXPA04006806A (https=)
NO (1) NO20043370L (https=)
NZ (1) NZ533750A (https=)
PL (1) PL371432A1 (https=)
RU (1) RU2312105C9 (https=)
TW (1) TWI328007B (https=)
WO (1) WO2003059893A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2004018435A1 (en) 2002-08-24 2004-03-04 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0302304D0 (sv) * 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
WO2005023771A1 (ja) * 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
WO2006020830A2 (en) * 2004-08-12 2006-02-23 Amgen Inc. Bisaryl-sulfonamides
EP2311827A1 (en) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
TW200800921A (en) * 2005-09-19 2008-01-01 Astrazeneca Ab Novel compounds
WO2007063935A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP5140154B2 (ja) 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
JP5492189B2 (ja) * 2008-04-09 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr10アンタゴニストである2−スルホニルアミノ−4−ヘテロアリールブチロアミド
US8673908B2 (en) 2008-11-10 2014-03-18 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
ES2556235T3 (es) * 2009-04-22 2016-01-14 Axikin Pharmaceuticals, Inc. Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
KR101840503B1 (ko) * 2010-12-16 2018-03-20 알러간, 인코포레이티드 케모카인 수용체 조절제로서의 신규한 1,2-비스-설폰아마이드 유도체
EP3312173B1 (en) 2011-11-09 2021-12-22 Kyowa Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
JP6327803B2 (ja) * 2013-07-09 2018-05-23 久慶 ▲ふく▼楊 大出力高効率単相多極発電機
CN106008418A (zh) * 2016-05-20 2016-10-12 厦门大学 一种5-氨甲基-2-呋喃甲醇的合成方法
DK3743418T3 (da) * 2018-01-26 2024-09-09 Rapt Therapeutics Inc Chemokinreceptormodulatorer og anvendelser deraf
CN113069446B (zh) * 2021-03-01 2022-12-02 中山亿维迪科技有限公司 El102在制备治疗新型冠状病毒所致疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143024A (en) * 1873-09-23 Improvement in clothes-pins
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
CA2162630C (en) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
AU2002358390A1 (en) 2001-12-18 2003-06-30 Astrazeneca Ab Novel compounds
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301654D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0302304D0 (sv) 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
TW200800921A (en) 2005-09-19 2008-01-01 Astrazeneca Ab Novel compounds
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds

Similar Documents

Publication Publication Date Title
JP2005521650A5 (https=)
RU2312105C9 (ru) N-пиразинилфенилсульфонамиды и их применение при лечении опосредованных хемокинами заболеваний
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP2005511543A5 (https=)
JP2005538955A5 (https=)
JP2021504443A5 (https=)
RU2003112610A (ru) Производные пиразола для лечения вирксных заболеваний
JP2017537948A5 (https=)
JP2004521087A5 (https=)
JP2010505809A5 (https=)
JP2004524301A5 (https=)
JP2007511485A5 (https=)
JP2004504301A5 (https=)
JP2007502821A5 (https=)
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2007186518A5 (https=)
JP2005534672A5 (https=)
JP2007519692A5 (https=)
JP2014525937A5 (https=)
RU2005108668A (ru) Индолы, обладающие противодиабетической активностью
JP2008505171A5 (https=)
JP2006506380A5 (https=)
JP2006508987A5 (https=)
CN101918395A (zh) 三唑联噁二唑衍生物
CA2416874A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists